Genetically Engineered Bacteriocins and their Potential as the Next Generation of Antimicrobials
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The discovery of penicillin by Fleming in 1928 was an historical milestone in the fight against infectious disease. Over the following fifty years, pharmaceutical companies discovered and developed over 100 antibiotics effective against a wide range of human pathogens. More recently, the dramatic rise in antibiotic-resistant pathogens has stimulated renewed efforts to identify, develop or redesign antibiotics active against these multi-resistant bacteria. This review focuses on such efforts directed at one large and highly diverse family of toxins, the bacteriocins, which hold great promise as the next generation of antimicrobials. The majority of bacteriocins differ from traditional antibiotics in one critical way: they have a relatively narrow killing spectrum and are, therefore, toxic only to bacteria closely related to the producing strain. Accordingly, they can be considered "designers drugs" that target specific bacterial pathogens. In this review we focus on recent attempts to generate custom designed bacteriocins using genetic engineering techniques. These efforts illustrate the potential of genetically-modified bacteriocins to solve some of the most challenging problems in disease control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bacteriocins: safe, natural antimicrobials for food preservation.
Cleveland, J., Montville, T. J., Nes, I. F., & Chikindas, M. L. (2001) · International Journal of Food Microbiology · doi:10.1016/s0168-1605(01)00560-8 · Cited by 1,835 · cited 1×
“The potential use of lantibiotics in food, human and animal health applications has been well documented [19, 62-64], with several features making them particularly attractive for such applications; a relatively broad killing spectrum, an auto-regulation system, stability and costeffective production processes [19, 27…”
Background
Cited by
Biomedical applications of nisin
Shin, J. M., Gwak, J. W., Kamarajan, P., Fenno, J. C., Rickard, A. H., & Kapila, Y. L. (2016) · Journal of Applied Microbiology · doi:10.1111/jam.13033 · Cited by 607
Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection
Ducarmon, Q. R., Zwittink, R. D., Hornung, B. V. H., van Schaik, W., Young, V. B., & Kuijper, E. J. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00007-19 · Cited by 566
Simons, A., Alhanout, K., & Duval, R. E. (2020) · Microorganisms · doi:10.3390/microorganisms8050639 · Cited by 547
The role of lactobacilli and probiotics in maintaining vaginal health
Borges, S., Silva, J., & Teixeira, P. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-013-3064-9 · Cited by 397
Novel biotechnological applications of bacteriocins: A review
Balciunas, E. M., Castillo Martinez, F. A., Todorov, S. D., Franco, B. D. G. D. M., Converti, A., & Oliveira, R. P. D. S. (2013) · Food Control · doi:10.1016/j.foodcont.2012.11.025 · Cited by 392
Metadata
- Authors
- Gillor, O., Nigro, L., & Riley, M.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-03-01
- Volume
- 11
- Issue
- 8
- Pages
- 1067-1075
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2154382675
- Cited by
- 143
- References
- 1
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetically Engineered Bacteriocins and their Potential as the Next Generation of Antimicrobials. https://app.cochat.ai/papers/10.2174/1381612053381666
- The paper
- Gillor, O., Nigro, L., & Riley, M. (2005). Genetically Engineered Bacteriocins and their Potential as the Next Generation of Antimicrobials. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053381666
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.